Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$126.97 - $287.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)482.20K
Market Cap
$31.04B
Enterprise Value$22.17B
Total Cash (Recent Filing)$2.63B
Total Debt (Recent Filing)$1.08B
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 01, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.13
Shares Outstanding97,863,060
10 Day Avg. Volume779,537
30 Day Avg. Volume482,203
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.61
Price to Cash Flow (P/CF)96.50
P/FCF Ratio78.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.89
Enterprise Value/Ebitda-55.80
Forecast
1Y Price Target
$324.65Price Target Upside26.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
EarningsBeiGene reported a blowout quarter exceeding analyst and consensus expectations, with Brukinsa overtaking Calquence in the U.S. market.
Product ApprovalTevimbra received approval as a treatment for 1L esophageal squamous cell carcinoma in the U.S., providing a potential tailwind to future revenue guidance.
Revenue GuidanceThe company provided total revenue guidance for 2025 in the range of $4.9-$5.3B, well ahead of analyst estimates of $4.6B.
Bears Say
ExpensesBeigene’s R&D/SG&A expense rose by 10%/21% YoY, but the company’s loss from operations narrowed to US$568.2mn in 2024 from US$1,207.7mn in 2023.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ONC FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $287.88 in the past 12 months.
What is BeiGene’s market cap?
BeiGene’s market cap is $31.04B.
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is May 01, 2025 which is in 56 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on Feb 27, 2025. The company reported -$1.43 earnings per share for the quarter, missing the consensus estimate of -$1.012 by -$0.418.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -0.49.
How many shares outstanding does BeiGene have?
BeiGene has 97,863,060 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$1.43 in its last earnings report, missing expectations of -$1.012. Following the earnings report the stock price went up 7.483%.
Which hedge fund is a major shareholder of BeiGene?
Currently, no hedge funds are holding shares in ONC
---
BeiGene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$324.65 (26.17% Upside)
$324.65 (26.17% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 908.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $384.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.78%
12-Months-Change
Fundamentals
Return on Equity
-19.35%
Trailing 12-Months
Asset Growth
2.06%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is a global biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company is committed to delivering affordable and accessible medicines to patients worldwide. BeiGene's core products include Brukinsa (zanubrutinib), a BTK inhibitor, and tislelizumab, an anti-PD-1 antibody, among other oncology therapies. The company operates primarily within the biopharmaceutical sector, with research and development facilities in China, the United States, and Australia.
---
ONC Company Deck
---
ONC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and market leadership for BRUKINSA, along with robust R&D productivity. However, challenges remain in the competitive landscape and in achieving desired outcomes with fixed duration treatments. Overall, the positives significantly outweigh the negatives.Read More>---
ONC Stock 12 Month Forecast
Average Price Target
$324.65
▲(26.17% Upside)
Technical Analysis
Best Analysts Covering ONC
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+20.29%
reiterated a buy rating 14 days ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +20.29% per trade.
---